DK3294769T3 - Behandling for multipelt myelom (mm) - Google Patents

Behandling for multipelt myelom (mm) Download PDF

Info

Publication number
DK3294769T3
DK3294769T3 DK16723349.3T DK16723349T DK3294769T3 DK 3294769 T3 DK3294769 T3 DK 3294769T3 DK 16723349 T DK16723349 T DK 16723349T DK 3294769 T3 DK3294769 T3 DK 3294769T3
Authority
DK
Denmark
Prior art keywords
treatment
multiple myelom
myelom
Prior art date
Application number
DK16723349.3T
Other languages
Danish (da)
English (en)
Inventor
Stéphane Leclair
Jan Endell
Stefan Härtle
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Application granted granted Critical
Publication of DK3294769T3 publication Critical patent/DK3294769T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
DK16723349.3T 2015-05-13 2016-05-13 Behandling for multipelt myelom (mm) DK3294769T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15167597 2015-05-13
PCT/EP2016/060810 WO2016180958A1 (en) 2015-05-13 2016-05-13 Treatment for multiple myeloma (mm)

Publications (1)

Publication Number Publication Date
DK3294769T3 true DK3294769T3 (da) 2021-03-08

Family

ID=53174925

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16723349.3T DK3294769T3 (da) 2015-05-13 2016-05-13 Behandling for multipelt myelom (mm)

Country Status (24)

Country Link
US (2) US10533057B2 (enExample)
EP (1) EP3294769B1 (enExample)
JP (2) JP7160533B2 (enExample)
KR (1) KR20180008571A (enExample)
CN (1) CN107614530A (enExample)
AU (1) AU2016260895B2 (enExample)
CA (1) CA2984464C (enExample)
CY (1) CY1123982T1 (enExample)
DK (1) DK3294769T3 (enExample)
ES (1) ES2862708T3 (enExample)
HR (1) HRP20210552T1 (enExample)
HU (1) HUE054271T2 (enExample)
IL (1) IL255552B (enExample)
LT (1) LT3294769T (enExample)
MX (1) MX380557B (enExample)
PL (1) PL3294769T3 (enExample)
PT (1) PT3294769T (enExample)
RS (1) RS61668B1 (enExample)
RU (1) RU2723047C2 (enExample)
SG (1) SG11201708691VA (enExample)
SI (1) SI3294769T1 (enExample)
SM (1) SMT202100202T1 (enExample)
WO (1) WO2016180958A1 (enExample)
ZA (1) ZA201708386B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
PL3294769T3 (pl) * 2015-05-13 2021-07-05 Morphosys Ag Leczenie szpiczaka mnogiego (mm)
EP3484923A1 (en) 2016-07-15 2019-05-22 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
CN112739715A (zh) 2018-01-12 2021-04-30 武田药品工业株式会社 抗cd38抗体的皮下给药
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
US20210047427A1 (en) * 2018-03-28 2021-02-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
KR20210104736A (ko) * 2018-12-14 2021-08-25 모르포시스 아게 항체 제형
EP4588484A3 (en) * 2019-01-28 2025-10-15 Sanofi-Aventis U.S. LLC Methods of treating multiple myeloma
US20200308296A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
NZ548990A (en) 2004-02-06 2009-06-26 Morphosys Ag Anti-CD38 human antibodies and uses therefor
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US20090123950A1 (en) 2005-05-24 2009-05-14 Morphosys Ag Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
KR20150139636A (ko) 2005-10-12 2015-12-11 모르포시스 아게 인간 cd38에 특이적인 완전 인간 hucal gold-유도 치료 항체들의 생성 및 프로파일링
PT2068874E (pt) * 2006-08-07 2015-05-21 Abbvie Biotherapeutics Inc Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi
NZ576122A (en) * 2006-09-26 2012-09-28 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3613774A1 (en) * 2010-06-09 2020-02-26 Genmab A/S Antibodies against human cd38
CN103118706B (zh) * 2010-09-27 2016-05-18 莫佛塞斯公司 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl
US9738933B2 (en) * 2012-12-05 2017-08-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS
CN103421115B (zh) * 2013-09-02 2015-06-03 东南大学 一种cd38纳米抗体及应用
US20150118251A1 (en) * 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
EP3191187B1 (en) 2014-09-09 2021-07-28 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
PL3294769T3 (pl) * 2015-05-13 2021-07-05 Morphosys Ag Leczenie szpiczaka mnogiego (mm)

Also Published As

Publication number Publication date
US11591406B2 (en) 2023-02-28
ZA201708386B (en) 2019-06-26
RU2017137496A3 (enExample) 2019-06-13
HRP20210552T1 (hr) 2021-05-14
RU2017137496A (ru) 2019-06-13
CN107614530A (zh) 2018-01-19
IL255552B (en) 2022-01-01
MX2017014396A (es) 2018-03-23
SG11201708691VA (en) 2017-11-29
AU2016260895A1 (en) 2017-11-09
EP3294769A1 (en) 2018-03-21
RU2723047C2 (ru) 2020-06-08
PT3294769T (pt) 2021-04-13
AU2016260895B2 (en) 2021-08-05
CA2984464C (en) 2023-10-10
CA2984464A1 (en) 2016-11-17
US10533057B2 (en) 2020-01-14
LT3294769T (lt) 2021-04-26
ES2862708T3 (es) 2021-10-07
CY1123982T1 (el) 2022-05-27
HUE054271T2 (hu) 2021-08-30
JP2021130668A (ja) 2021-09-09
IL255552A (en) 2018-01-31
SI3294769T1 (sl) 2021-07-30
JP2018515513A (ja) 2018-06-14
EP3294769B1 (en) 2021-01-13
SMT202100202T1 (it) 2021-05-07
KR20180008571A (ko) 2018-01-24
MX380557B (es) 2025-03-12
US20190048091A1 (en) 2019-02-14
PL3294769T3 (pl) 2021-07-05
US20200079871A1 (en) 2020-03-12
RS61668B1 (sr) 2021-04-29
WO2016180958A1 (en) 2016-11-17
JP7160533B2 (ja) 2022-10-25

Similar Documents

Publication Publication Date Title
EP3344318A4 (en) Patient interfaces
DK3072835T3 (da) Fremgangsmåde til fremføring
EP3298448A4 (en) OPTOGENETIC MICROSCOPE
BR112017018413A2 (pt) tratamento de pancreatite
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3373874T3 (da) Medicinsk forbinding
PL3197456T3 (pl) Leczenie nowotworów
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
ITUB20153347A1 (it) Apparato per la videocomunicazione
DK3294769T3 (da) Behandling for multipelt myelom (mm)
DK3341479T3 (da) LNA-G-Proces
EP3345473A4 (en) HARVESTER
EP3375108A4 (en) SELECTIVE WIFI
HUE057118T2 (hu) Folyamat
DK3517268T3 (da) Læggeenhed
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
EP3351087A4 (en) HARVESTER
EP3373875A4 (en) BANDAGE
DK3597189T3 (da) Krystallinske forbindelser
HUE043622T2 (hu) Tároló
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
EP3272204A4 (en) HARVESTER
EP3334447A4 (en) CCK2R-drug conjugates
DK3307184T3 (da) Implantatfjerner
EP3539492C0 (en) BONE PLATES